207 related articles for article (PubMed ID: 15028483)
21. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
22. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Saravolatz LD; Leggett J
Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
[TBL] [Abstract][Full Text] [Related]
23. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
[TBL] [Abstract][Full Text] [Related]
24. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Segreti J; Jones RN; Bertino JS
J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
[TBL] [Abstract][Full Text] [Related]
25. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Allen GP; Hankins CD
J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
[TBL] [Abstract][Full Text] [Related]
27. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
[TBL] [Abstract][Full Text] [Related]
28. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Hoepelman I
Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
[TBL] [Abstract][Full Text] [Related]
29. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Blondeau J
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S64-7. PubMed ID: 16257312
[TBL] [Abstract][Full Text] [Related]
30. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Stein GE; Schooley S
Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
[TBL] [Abstract][Full Text] [Related]
31. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
32. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Deramo VA; Lai JC; Fastenberg DM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
[TBL] [Abstract][Full Text] [Related]
33. Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection.
Oliveira AD; Höfling-Lima AL; Belfort R; Gayoso Mde F; Francisco W
Arq Bras Oftalmol; 2007; 70(2):286-9. PubMed ID: 17589701
[TBL] [Abstract][Full Text] [Related]
34. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Fintelmann RE; Hoskins EN; Lietman TM; Keenan JD; Gaynor BD; Cevallos V; Acharya NR
Arch Ophthalmol; 2011 Apr; 129(4):399-402. PubMed ID: 21482865
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods.
Somasundaram S; Paramasivan NC
Chemotherapy; 2006; 52(4):190-5. PubMed ID: 16714850
[TBL] [Abstract][Full Text] [Related]
36. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Kim SJ; Toma HS
Ophthalmology; 2011 Jul; 118(7):1358-63. PubMed ID: 21420176
[TBL] [Abstract][Full Text] [Related]
37. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
38. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
39. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Ozdek SC; Miller D; Flynn PM; Flynn HW
Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
[TBL] [Abstract][Full Text] [Related]
40. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Kim JM; Kim JS; Kim N; Jung HC; Song IS
J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
